Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Trapping and dissociation of propafenone derivatives in HERG channels.
Windisch A
,
Timin E
,
Schwarz T
,
Stork-Riedler D
,
Erker T
,
Ecker G
,
Hering S
.
???displayArticle.abstract???
BACKGROUND AND PURPOSE: Human ether-a-go-go related gene (HERG) channel inhibitors may be subdivided into compounds that are trapped in the closed channel conformation and others that dissociate at rest. The structural peculiarities promoting resting state dissociation from HERG channels are currently unknown. A small molecule-like propafenone is efficiently trapped in the closed HERG channel conformation. The aim of this study was to identify structural moieties that would promote dissociation of propafenone derivatives.
EXPERIMENTAL APPROACH: Human ether-a-go-go related gene channels were heterologously expressed in Xenopus oocytes and potassium currents were recorded using the two-microelectrode voltage clamp technique. Recovery from block by 10 propafenone derivatives with variable side chains, but a conserved putative pharmacophore, was analysed.
KEY RESULTS: We have identified structural determinants of propafenone derivatives that enable drug dissociation from the closed channel state. Propafenone and four derivatives with 'short' side chains were trapped in the closed channel. Five out of six bulky derivatives efficiently dissociated from the channel at rest. One propafenone derivative with a similar bulk but lacking an H-bond acceptor in this region was trapped. Correlations were observed between molecular weight and onset of channel block as well as between pK(a) and recovery at rest.
CONCLUSION AND IMPLICATIONS: The data show that extending the size of a trapped HERG blocker-like propafenone by adding a bulky side chain may impede channel closure and thereby facilitate drug dissociation at rest. The presence of an H-bond acceptor in the bulky side chain is, however, essential.
Arias,
Effects of propafenone and its main metabolite, 5-hydroxypropafenone, on HERG channels.
2003, Pubmed
Arias,
Effects of propafenone and its main metabolite, 5-hydroxypropafenone, on HERG channels.
2003,
Pubmed
Baburin,
Automated fast perfusion of Xenopus oocytes for drug screening.
2006,
Pubmed
,
Xenbase
Campbell,
Importance of physico-chemical properties in determining the kinetics of the effects of Class I antiarrhythmic drugs on maximum rate of depolarization in guinea-pig ventricle.
1983,
Pubmed
Carmeliet,
Voltage- and time-dependent block of the delayed K+ current in cardiac myocytes by dofetilide.
1992,
Pubmed
Chiba,
Structural requirements for activity of propafenone-type modulators in P-glycoprotein-mediated multidrug resistance.
1996,
Pubmed
Courtney,
Structure-activity relations for frequency-dependent sodium channel block in nerve by local anesthetics.
1980,
Pubmed
Decher,
Binding site of a novel Kv1.5 blocker: a "foot in the door" against atrial fibrillation.
2006,
Pubmed
,
Xenbase
Fermini,
The impact of drug-induced QT interval prolongation on drug discovery and development.
2003,
Pubmed
Haverkamp,
The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology.
2000,
Pubmed
Hille,
Local anesthetics: hydrophilic and hydrophobic pathways for the drug-receptor reaction.
1977,
Pubmed
Kamiya,
Open channel block of HERG K(+) channels by vesnarinone.
2001,
Pubmed
,
Xenbase
Kamiya,
Molecular determinants of HERG channel block.
2006,
Pubmed
,
Xenbase
Keating,
Molecular and cellular mechanisms of cardiac arrhythmias.
2001,
Pubmed
Kikuchi,
Blockade of HERG cardiac K+ current by antifungal drug miconazole.
2005,
Pubmed
Klein,
Similarity based SAR (SIBAR) as tool for early ADME profiling.
2002,
Pubmed
Mitcheson,
Molecular determinants of high-affinity drug binding to HERG channels.
2003,
Pubmed
Mitcheson,
hERG potassium channels and the structural basis of drug-induced arrhythmias.
2008,
Pubmed
Mitcheson,
Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate.
2000,
Pubmed
,
Xenbase
NULL,
Guide to Receptors and Channels (GRAC), 4th Edition.
2009,
Pubmed
Perry,
Structural determinants of HERG channel block by clofilium and ibutilide.
2004,
Pubmed
,
Xenbase
Sanguinetti,
A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel.
1995,
Pubmed
,
Xenbase
Sanguinetti,
Mutations of the S4-S5 linker alter activation properties of HERG potassium channels expressed in Xenopus oocytes.
1999,
Pubmed
,
Xenbase
Sanguinetti,
hERG potassium channels and cardiac arrhythmia.
2006,
Pubmed
Stork,
State dependent dissociation of HERG channel inhibitors.
2007,
Pubmed
,
Xenbase
Sánchez-Chapula,
Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+ channel block.
2002,
Pubmed
,
Xenbase
Thai,
The hERG potassium channel and drug trapping: insight from docking studies with propafenone derivatives.
2010,
Pubmed
Tseng,
I(Kr): the hERG channel.
2001,
Pubmed
Viskin,
Long QT syndromes and torsade de pointes.
1999,
Pubmed
Witchel,
The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.
2004,
Pubmed
,
Xenbase
Yeh,
Immobilisation of gating charge by a substance that simulates inactivation.
1978,
Pubmed
Yeh,
Molecular and structural basis of resting and use-dependent block of sodium current defined using disopyramide analogues.
1987,
Pubmed
Zou,
Single HERG delayed rectifier K+ channels expressed in Xenopus oocytes.
1997,
Pubmed
,
Xenbase
